- Home
- LGVN vs BDRX Comparison
LGVN vs BDRX Comparison
Compare LGVN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- BDRX
- Stock Information
- Founded
- LGVN 2014
- BDRX 2000
- Country
- LGVN United States
- BDRX United Kingdom
- Employees
- LGVN N/A
- BDRX N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- BDRX Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- BDRX Health Care
- Exchange
- LGVN Nasdaq
- BDRX Nasdaq
- Market Cap
- LGVN 23.4M
- BDRX 5.8M
- IPO Year
- LGVN 2021
- BDRX N/A
- Fundamental
- Price
- LGVN $1.43
- BDRX $0.87
- Analyst Decision
- LGVN Strong Buy
- BDRX
- Analyst Count
- LGVN 3
- BDRX 0
- Target Price
- LGVN $8.67
- BDRX N/A
- AVG Volume (30 Days)
- LGVN 710.2K
- BDRX 3.1M
- Earning Date
- LGVN 08-13-2025
- BDRX 04-11-2025
- Dividend Yield
- LGVN N/A
- BDRX N/A
- EPS Growth
- LGVN N/A
- BDRX N/A
- EPS
- LGVN N/A
- BDRX N/A
- Revenue
- LGVN $2,225,000.00
- BDRX N/A
- Revenue This Year
- LGVN N/A
- BDRX N/A
- Revenue Next Year
- LGVN $51.48
- BDRX N/A
- P/E Ratio
- LGVN N/A
- BDRX N/A
- Revenue Growth
- LGVN 127.50
- BDRX N/A
- 52 Week Low
- LGVN $1.14
- BDRX $0.78
- 52 Week High
- LGVN $4.94
- BDRX $41.50
- Technical
- Relative Strength Index (RSI)
- LGVN 59.84
- BDRX 38.67
- Support Level
- LGVN $1.27
- BDRX $0.85
- Resistance Level
- LGVN $1.40
- BDRX $0.92
- Average True Range (ATR)
- LGVN 0.11
- BDRX 0.06
- MACD
- LGVN 0.04
- BDRX 0.01
- Stochastic Oscillator
- LGVN 61.40
- BDRX 32.73
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.